Risperidone-associated diabetes mellitus: A pharmacovigilance study

Pharmacotherapy

Volumn 23, Issue 6, 2003, Pages 735-744

  Koller, Elizabeth A ^a   Cross, James T ^a   Doraiswamy, P Murali ^b   Schneider, Bruce S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ACIDOSIS; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; FEMALE; FOOD AND DRUG ADMINISTRATION; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPEROSMOLAR COMA; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PUBLICATION; REVIEW; RISK FACTOR; SCHOOL CHILD; SEX RATIO;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHILD; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HALOPERIDOL; HUMANS; HYPERGLYCEMIA; MALE; MEDLINE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; RISPERIDONE; UNITED STATES;

EID: 0038689155     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.6.735.32178     Document Type: Review

References (47)

1. Anonymous. Risperidone. Physicians' desk reference. Montvale, NJ: Medical Economics, 2003:1786-90.
2. Kiraly SJ, Gibson RE, Ancill RJ, Holliday SG. Risperidone: treatment response in adult and geriatric patients. Int J Psychiatry Med 1998;28:255-63.
3. Krashin D, Oates EW. Risperidone as adjunct therapy for post-traumatic stress disorder. Mil Med 1999;164:605-6.
4. Zarate CA Jr, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-17.
5. Yatham LN. The role of novel antipsychotics in bipolar disorders. J Clin Psychol 2002;63:10-4.
6. 2 receptors. Int Clin Psychopharmacol 1995;10:19-30.
7. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In: Hardmman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman and Gilman's: the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:399-430.
8. Mannens G, Huang ML, Meuldermans W, Hendricks J, Woestenberghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-41.
9. Eap CB, Bondolfi G, Zullino D, et al. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 2001;23:228-31.
10. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
11. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship to CYP2D6 genotypes. Psychopharmacology (Berl) 2002;162:50-54.
12. Lindenmayer J-P, Nathan A-M, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62 (suppl 23):30-8.
13. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998;8:151-9.
14. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000;41:369-70.
15. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone: associated new-onset diabetes. Biol Psychiatry 2001;50:148-9.
16. Brescan DW. Risperidone and glucose intolerance [abstr]. Presented at the 150th annual meeting of the American Psychiatric Association, San Diego, CA., May 17-22, 1997.
17. Hidaka S. Two cases of perforation of the colon in long-term hospitalized schizophrenic patients during psychotropic drug administration. Clin Psychiatry 1999;41:425-8.
18. Litovitz T. 1988 annual report of the American Association of Poison Control Centers national data collection system. Am J Emerg Med 1989;7:495-545.
19. Litovitz T. 1990 annual report of the American Association of Poison Control Centers national data collection system. Am J Emerg Med 1991;9:461-509.
20. Litovitz T. 1994 annual report of the American Association of Poison Control Centers national data collection system. Am J Emerg Med 1995;13:551-97.
21. Miyahira Y. A case report of death from neuroleptic malignancy syndrome due to long-acting haloperidol. Kyushu Neuropsychiatry 1998;44:322-3.
22. Capron M, Lafitte B, Benedit M, et al. Necrotizing colitis in a 29-year-old man under high-dose neuroleptics (French). Reanim Urgences 1999;8:701-4.
23. Dharmarajan TS, Bullecer MF, Gorich G. Drug-related hyperthermia. J Am Med Dir Assoc 2001;2:160-5.
24. Dohin-Caplanne S. Severe hepatitis complicating exercise-induced heatstroke favored by treatment with neuroleptic and anticholinergic drugs (French). Gastroenterol Clin Biol 1995;19:637-8.
25. Litovitz T. 1987 annual report of the American Association of Poison Control Centers national data collection system. Am J Emerg Med 1988;6:479-515.
26. Litovitz T. 1998 annual report of the American Association of Poison Control Centers national data collection system. Am J Emerg Med 1999;17:435-87.
27. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America, 2nd ed. Publication no. 95-1468. Bethesda, MD: National Institutes of Health-National Institute of Diabetes, Digestive, and Kidney Diseases, 1995:47-67.
28. Ammon HR, Orci L, Steinle J. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther 1973;187:423-9.
29. Isojarvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001;111:290-6.
30. Jallon P, Picard F. Body weight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-78.
31. Odinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9.
32. Turnbull DM, Bone AJ, Tames FJ, Wilson L, Baird JD, Sherratt HS. The effect of valproate on blood metabolite concentrations in spontaneously diabetic, ketoacidotic, BB/E Wistar rats. Diabetes Res 1985;2:45-8.
33. Brewer T, Colditz G. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281:824-9.
34. Lasser KE, Allen PD, Woolhandler SF, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
35. Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel: a need for new approaches to drug safety. N Engl J Med 2000;342:1824-6.
36. Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry 2002;41:495-6.
37. Koller EA, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes mellitus. Am J Med 2001;111:716-23.
38. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-52.
39. Procyshyn RM, Pande S, Tse G. New-onset diabetes associated with quetiapine. Can J Psychiatry 2000;45:668-9.
40. Sobel M, Jaggers ED, Franz MA. New-onset diabetes associated with the initiation of quetiapine treatment. J Clin Psychol 1999;60:556-7.
41. Lacruz A, Baptista T, Mendoza S, Mendoza-Guillen JM, Hernandez L. Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin, and body weight during sulpiride treatment. Mol Psychiatry 2000;5:70-6.
42. Melkersson K, Hulting A-L, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999;60:783-91.
43. Melkersson K, Hulting A-L, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-9.
44. Melkersson K, Khan A, Hilding A, Hulting A-L. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 2001;11:327-32.
45. Ardizzone TD, Bradley RJ, Freeman III AM, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogues of clozapine. Brain Res 2001;923:82-90.
46. Dwyer DS, Liu Ye, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neurosci Lett 1999;274:151-4.
47. Koller, EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis associated with atypical antipsychotics: from the FDA MedWatch surveillance system. Pharmacotherapy, in press.